Literature DB >> 33220622

Practitioners' experiences of using Gut Directed Hypnosis for irritable bowel syndrome: Perceived impact upon client wellbeing: A qualitative study.

Laura Pemberton1, Lauren Kita2, Katrina Andrews2.   

Abstract

Gut Directed Hypnosis (GDH) is a specialised form of hypnotherapy originally developed to reduce gastrointestinal (GI) symptoms in individuals with Irritable Bowel Syndrome (IBS). IBS is a condition characterised by symptoms including bloating, abdominal pain and diarrhoea and/or constipation as well as psychosocial symptoms such as depression and anxiety. Although the specific mechanism of action remains unclear, it is suggested that GDH works on the brain-gut axis to improve GI symptoms, psychological functioning and overall wellbeing. The present study aimed to expand upon the knowledge surrounding GDH by exploring practitioners' experiences of using GDH for IBS and their perceptions of how it impacts upon client wellbeing. Six practitioners trained in GDH participated in one hour semi-structured interviews. Thematic Analyses (TA) was used to analyse data. Three major themes emerged from data including: predisposing personality traits and vulnerabilities associated with IBS; GDH as evidence-based practice; and the future evolution of GDH. The findings from this study add to the growing body of literature exploring the use of GDH for IBS, by incorporating the perspective of practitioners working within this field.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Gut directed hypnotherapy; Hypnosis; IBS; Irritable bowel syndrome; Practitioners; Qualitative

Mesh:

Year:  2020        PMID: 33220622     DOI: 10.1016/j.ctim.2020.102605

Source DB:  PubMed          Journal:  Complement Ther Med        ISSN: 0965-2299            Impact factor:   2.446


  1 in total

1.  Hypnotherapy for irritable bowel syndrome: patient expectations and perceptions.

Authors:  Anne-Sophie Donnet; Syed Shariq Hasan; Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2022-02-15       Impact factor: 4.409

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.